Please assess the completion status of the following clinical trial:

Trial Title: CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients ≥ 19 years~* ≥ 6 months since the last stroke~* ≥ 2 points in the focal spasticity of wrist flexor and ≥ 1 point at least one of elbow flexor and finger flexor as measured on MAS(0 to 4)~* Informed consent has been obtained~Exclusion Criteria:~* Neuromuscular disorders such as Lambert-Eaton syndrome, myasthenia gravis, or amyotrophic lateral sclerosis~* History(within 4 months of screening visit) or planned(during study period) treatment with phenol or alcohol injection or surgery in the target limb~* History(within 4 months of screening visit) or planned(during study period) treatment with tendon lengthening in the target limb~* Fixed joint/muscle contracture~* Severe atrophy~* Concurrent treatment with an intrathecal baclofen~* Patients who have bleeding tendency or taking anti-coagulant~* Dysphagia and Breathing Difficulties~* History(within 4 months of screening visit) Planned(during study period) treatment with Botulinum Toxin~* Known allergy or sensitivity to study medication or its components~* Concurrent or planed Muscle relaxants and/or benzodiazepine medication If patient has taken these medication stable from one month before screening and no treatment changes are not planned during the study, participation is allowed.~* Current Physical, occupational, Splinting therapy These therapy regimens will be permitted if they have been stable in the one month before screening; no treatment and no changes are planned during the study.~* Patient who are participating in other clinical trials at the screening~* Females who are pregnant, breastfeeding, or planning a pregnancy during the study period, or female of childbearing potential, not using a reliable means of contraception.~* Patients who are not eligible for this study at the discretion of the investigator.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CORETOX® (Type: EXPERIMENTAL): None
- BOTOX® (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).